NCT05103904View on ClinicalTrials.gov

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

November 4, 2025

Study Completion Date

November 4, 2026

Conditions
Recurrent Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC V8Stage IIIA Hepatocellular Carcinoma AJCC V8Stage IIIB Hepatocellular Carcinoma AJCC V8Stage IV Hepatocellular Carcinoma AJCC V8Stage IVA Hepatocellular Carcinoma AJCC V8Stage IVB Hepatocellular Carcinoma AJCC V8Unresectable Hepatocellular Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenvatinib

Given PO

Trial Locations (3)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

35294

NOT_YET_RECRUITING

University of Alabama at Birmingham, Birmingham

85259

NOT_YET_RECRUITING

Mayo Clinic Arizona, Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Emory University

OTHER